Publications by authors named "Neil Senzer"

Claim this Profile
C
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rodney P Rocconi, Bradley J Monk, Adam Walter, Thomas J Herzog, Evanthia Galanis, Neil Senzer

Gynecol Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Stephen Mf Jamieson, Peter Tsai, Maria K Kondratyev, Pratha Budhani, Arthur Liu, Neil N Senzer

JCI Insight· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rodney P Rocconi, Laura Stanbery, Min Tang, Luciana Madeira da Silva, Adam Walter, Neil Senzer

Commun Med (Lond)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rodney P Rocconi, Bradley J Monk, Adam Walter, Thomas J Herzog, Evanthia Galanis, Neil Senzer

Gynecol Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].
Jonathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning

Gynecol Oncol Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.
Johnathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning

Gynecol Oncol Rep· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Matthew N Metzinger, Cherian Verghese, Danae M Hamouda, Amanda Lenhard, Khalil Choucair, Neil Senzer

Oncology· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Neil Senzer

Future Sci OA· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Stephen Mf Jamieson, Peter Tsai, Maria K Kondratyev, Pratha Budhani, Arthur Liu, Neil N Senzer

JCI Insight· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
Donald D Rao, Xiuquan Luo, Zhaohui Wang, Christopher M Jay, Francis C Brunicardi, Neil Senzer

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
Maurizio Ghisoli, McCarley Rutledge, Philip J Stephens, Robert Mennel, Minal Barve, Neil Senzer

J Pediatr Hematol Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery.
Zhaohui Wang, Christopher M Jay, Courtney Evans, Padmasini Kumar, Connor Phalon, Neil Senzer

Toxicol Sci· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Jonathan Oh, Minal Barve, Carolyn M Matthews, E Colin Koon, Thomas P Heffernan, Neil Senzer

Gynecol Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor vaccines and cellular immunotherapies.
John Nemunaitis, Neil Senzer, Leah Plato

Ann Transl Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.
Neil H Segal, Purvi Gada, Neil Senzer, Michele A Gargano, Myra L Patchen

Clin Colorectal Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Maurizio Ghisoli, Minal Barve, Robert Mennel, Carl Lenarsky, Staci Horvath, Neil Senzer

Mol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Donald D Rao, Christopher Jay, Zhaohui Wang, Xiuquan Luo, Padmasini Kumar, Neil Senzer

Mol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
Howard L Kaufman, Thomas Amatruda, Tony Reid, Rene Gonzalez, John Glaspy, Neil N Senzer

J Immunother Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer

J Clin Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shedding New Light on the Use of Imaging Technology for Glioblastoma Tumor Resection.
John Nemunaitis, Neil Senzer

Mol Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
Minal Barve, Zhaohui Wang, Padmasini Kumar, Christopher M Jay, Xiuquan Luo, Neil Senzer

Mol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.
Maurizio Ghisoli, Minal Barve, Reva Schneider, Robert Mennel, Carl Lenarsky, Neil Senzer

Mol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.
Daniel W Bowles, Neil Senzer, Diana Hausman, Scott Peterson, Alex Vo

Invest New Drugs· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Devalingam Mahalingam, John J Nemunaitis, Laeeq Malik, John Sarantopoulos, Steven Weitman, Neil N Senzer

Cancer Chemother Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.
John Nemunaitis, Minal Barve, Douglas Orr, Joseph Kuhn, Mitchell Magee, Neil Senzer

Oncology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis